Tenofovir alafenamide for HIV infection: is less more?

This publication has 11 references indexed in Scilit:

• Tenofovir alafenamide versus tenofovir disoproxil fumarate, coformulated with elvitegravir, cobicistat, and emtricitabine, for initial treatment of HIV-1 infection: two randomised, double-blind, phase 3, non-inferiority trials
  The Lancet, 2015
• Association Between Antiretroviral Exposure and Renal Impairment Among HIV-Positive Persons With Normal Baseline Renal Function: the D:A:D Studya
  The Journal of Infectious Diseases, 2013
• Antiretroviral Prophylaxis for HIV Prevention in Heterosexual Men and Women
  New England Journal of Medicine, 2012
• Association of tenofovir exposure with kidney disease risk in HIV infection
  AIDS, 2012
• Life Expectancy of Persons Receiving Combination Antiretroviral Therapy in Low-Income Countries: A Cohort Analysis From Uganda
  Annals of Internal Medicine, 2011
• Bone Mineral Density and Fractures in Antiretroviral-Naive Persons Randomized to Receive Abacavir-Lamivudine or Tenofovir Disoproxil Fumarate-Emtricitabine Along With Efavirenz or Atazanavir-Ritonavir: AIDS Clinical Trials Group A5224s, a Substudy of ACTG A5202
  The Journal of Infectious Diseases, 2011
• Preexposure Chemoprophylaxis for HIV Prevention in Men Who Have Sex with Men
  New England Journal of Medicine, 2010
• Scaling Up the 2010 World Health Organization HIV Treatment Guidelines in Resource-Limited Settings: A Model-Based Analysis
  PLOS Medicine, 2010
• Systematic Review and Meta‐analysis: Renal Safety of Tenofovir Disoproxil Fumarate in HIV‐Infected Patients
  Clinical Infectious Diseases, 2010
• Life expectancy of individuals on combination antiretroviral therapy in high-income countries: a collaborative analysis of 14 cohort studies
  The Lancet, 2008